505 related articles for article (PubMed ID: 9467543)
1. Bone mineral density and body composition before and during treatment with gonadotropin-releasing hormone agonist in children with central precocious and early puberty.
Boot AM; De Muinck Keizer-Schrama S; Pols HA; Krenning EP; Drop SL
J Clin Endocrinol Metab; 1998 Feb; 83(2):370-3. PubMed ID: 9467543
[TBL] [Abstract][Full Text] [Related]
2. Longitudinal follow-up of bone density and body composition in children with precocious or early puberty before, during and after cessation of GnRH agonist therapy.
van der Sluis IM; Boot AM; Krenning EP; Drop SL; de Muinck Keizer-Schrama SM
J Clin Endocrinol Metab; 2002 Feb; 87(2):506-12. PubMed ID: 11836277
[TBL] [Abstract][Full Text] [Related]
3. Changes in bone mineral density, body composition, and lipid metabolism during growth hormone (GH) treatment in children with GH deficiency.
Boot AM; Engels MA; Boerma GJ; Krenning EP; De Muinck Keizer-Schrama SM
J Clin Endocrinol Metab; 1997 Aug; 82(8):2423-8. PubMed ID: 9253311
[TBL] [Abstract][Full Text] [Related]
4. Bone mineral density and body composition in short children born SGA during growth hormone and gonadotropin releasing hormone analog treatment.
Lem AJ; van der Kaay DC; Hokken-Koelega AC
J Clin Endocrinol Metab; 2013 Jan; 98(1):77-86. PubMed ID: 23125290
[TBL] [Abstract][Full Text] [Related]
5. Bone mass at final height in precocious puberty after gonadotropin-releasing hormone agonist with and without calcium supplementation.
Antoniazzi F; Zamboni G; Bertoldo F; Lauriola S; Mengarda F; Pietrobelli A; Tatò L
J Clin Endocrinol Metab; 2003 Mar; 88(3):1096-101. PubMed ID: 12629090
[TBL] [Abstract][Full Text] [Related]
6. Changes in bone mineral density and body composition in children with central precocious puberty and early puberty before and after one year of treatment with GnRH agonist.
Ko JH; Lee HS; Lim JS; Kim SM; Hwang JS
Horm Res Paediatr; 2011; 75(3):174-9. PubMed ID: 20881364
[TBL] [Abstract][Full Text] [Related]
7. Effect of growth hormone therapy and puberty on bone and body composition in children with idiopathic short stature and growth hormone deficiency.
Högler W; Briody J; Moore B; Lu PW; Cowell CT
Bone; 2005 Nov; 37(5):642-50. PubMed ID: 16139578
[TBL] [Abstract][Full Text] [Related]
8. Prevention of bone demineralization by calcium supplementation in precocious puberty during gonadotropin-releasing hormone agonist treatment.
Antoniazzi F; Bertoldo F; Lauriola S; Sirpresi S; Gasperi E; Zamboni G; Tatò L
J Clin Endocrinol Metab; 1999 Jun; 84(6):1992-6. PubMed ID: 10372699
[TBL] [Abstract][Full Text] [Related]
9. Spinal and femoral bone mass accumulation during normal adolescence: comparison with female patients with sexual precocity and with hypogonadism.
Takahashi Y; Minamitani K; Kobayashi Y; Minagawa M; Yasuda T; Niimi H
J Clin Endocrinol Metab; 1996 Mar; 81(3):1248-53. PubMed ID: 8772607
[TBL] [Abstract][Full Text] [Related]
10. The effect of short- and long-term growth hormone treatment on bone mineral density and bone metabolism of prepubertal children with idiopathic short stature: a 3-year study.
Lanes R; Gunczler P; Esaa S; Weisinger JR
Clin Endocrinol (Oxf); 2002 Dec; 57(6):725-30. PubMed ID: 12460321
[TBL] [Abstract][Full Text] [Related]
11. Quantitative calcaneal ultrasound parameters and bone mineral density at final height in girls treated with depot gonadotrophin-releasing hormone agonist for central precocious puberty or idiopathic short stature.
Kapteijns-van Kordelaar S; Noordam K; Otten B; van den Bergh J
Eur J Pediatr; 2003 Nov; 162(11):776-80. PubMed ID: 13680381
[TBL] [Abstract][Full Text] [Related]
12. Bone mineral density and bone turnover before and after surgical cure of Cushing's syndrome.
Hermus AR; Smals AG; Swinkels LM; Huysmans DA; Pieters GF; Sweep CF; Corstens FH; Kloppenborg PW
J Clin Endocrinol Metab; 1995 Oct; 80(10):2859-65. PubMed ID: 7559865
[TBL] [Abstract][Full Text] [Related]
13. Long-term outcome after depot gonadotropin-releasing hormone agonist treatment of central precocious puberty: final height, body proportions, body composition, bone mineral density, and reproductive function.
Heger S; Partsch CJ; Sippell WG
J Clin Endocrinol Metab; 1999 Dec; 84(12):4583-90. PubMed ID: 10599723
[TBL] [Abstract][Full Text] [Related]
14. Bone mineral density and body composition in Thai Precocious Puberty girls treated with GnRH agonist.
Wacharasindhu S; Petwijit T; Aroonparkmongkol S; Srivuthana S; Kingpetch K
J Med Assoc Thai; 2006 Aug; 89(8):1194-8. PubMed ID: 17048429
[TBL] [Abstract][Full Text] [Related]
15. Bone mineral density and effects of growth hormone treatment in prepubertal children with Prader-Willi syndrome: a randomized controlled trial.
de Lind van Wijngaarden RF; Festen DA; Otten BJ; van Mil EG; Rotteveel J; Odink RJ; van Leeuwen M; Haring DA; Bocca G; Mieke Houdijk EC; Hokken-Koelega AC
J Clin Endocrinol Metab; 2009 Oct; 94(10):3763-71. PubMed ID: 19622627
[TBL] [Abstract][Full Text] [Related]
16. Long-term effects of growth hormone (GH) on bone mineral status and bone turnover markers in patients with isolated GH deficiency and multiple pituitary hormone deficiency.
Gonc EN; Kandemir N
Clin Endocrinol (Oxf); 2007 May; 66(5):672-7. PubMed ID: 17381489
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of bone density in girls with precocious and early puberty during treatment with GnRH agonist.
Assa A; Weiss M; Aharoni D; Mor A; Rachmiel M; Bistritzer T
J Pediatr Endocrinol Metab; 2011; 24(7-8):505-10. PubMed ID: 21932589
[TBL] [Abstract][Full Text] [Related]
18. Impaired development of bone mineral density during chemotherapy: a prospective analysis of 46 children newly diagnosed with cancer.
Arikoski P; Komulainen J; Riikonen P; Parviainen M; Jurvelin JS; Voutilainen R; Kröger H
J Bone Miner Res; 1999 Dec; 14(12):2002-9. PubMed ID: 10620058
[TBL] [Abstract][Full Text] [Related]
19. Longitudinal changes in bone mineral density and bone turnover in postmenopausal women with primary hyperparathyroidism.
Guo CY; Thomas WE; al-Dehaimi AW; Assiri AM; Eastell R
J Clin Endocrinol Metab; 1996 Oct; 81(10):3487-91. PubMed ID: 8855790
[TBL] [Abstract][Full Text] [Related]
20. Serum concentrations of type I and III procollagen propeptides in healthy children and girls with central precocious puberty during treatment with gonadotropin-releasing hormone analog and cyproterone acetate.
Hertel NT; Stoltenberg M; Juul A; Main KM; Müller J; Nielsen CT; Lorenzen I; Skakkebaek NE
J Clin Endocrinol Metab; 1993 Apr; 76(4):924-7. PubMed ID: 8473407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
